Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events
References (60)
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Gastroenterology
(2001)- et al.
National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs
Gastroenterology
(2005) - et al.
COX-2 selectivity alone does not define the cardiovascular risks associated with nonsteroidal anti-inflammatory drugs
Lancet
(2008) - et al.
Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population
Gastroenterology
(2007) - et al.
Stratifying the risk of NSAIDrelated upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Gastroenterology
(2002) - et al.
Aspirin use among US adults: Behavioral Risk Factor Surveillance System
Am J Prev Med
(2006) - et al.
Summing the risk of NSAID therapy
Lancet
(2007) - et al.
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAI D use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
J Am Coll Cardiol
(2008) - et al.
Osteoarthritis Research Society International (OARSI) recom mendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
Osteoarthritis Cartilage
(2008) - et al.
Celecoxib compared with lansoprazole and naproxen to prevent gas trointestinal ulcer complications
Am J Med
(2005)
Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapyversus coxibs
Gastroenterology
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibi tor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial
Lancet
Ulcer recurrence in high-risk patients receiving non steroidal anti-inflammatory drugs plus low-dose aspirin: Results of a post hoc subanalysis
Clin Ther
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: A randomized, double-blind, endoscopic trial
Clin Gastroenterol Hepatol
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients
Clin Ther
Adherence with multiplecombination anti hypertensive phar macotherapies in a US managed care database
Clin Ther
Silent peptic ulceration: Deadly silence or golden silence?
Gastroenterology
Fixed-dose combinations improve medication compliance: A meta-analysis
Am J Med
Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults
Pharmacoepidemiol Drug Saf
Inappropriate prevention of NSAI Dinduced gastrointestinal events among long-term users in the elderly
Drugs Aging
The impact of nonsteroidal anti-inflammatory drug-induced gastropathy
Am J Manag Care
Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
Arch Intern Med
Underutilization of preventive strategies inpatients receiving NSAIDs
Rheumatology (Oxford)
Underutilisation of gastroprotective drugs in patients with NSAID-related ulcers
Gastrointestinal toxicity of nonsteroidal anti inflammatory drugs
N Engl J Med
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti inflammatory drugs. A randomized, double-blind, placebocontrolled trial
Ann Intern Med
A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti inflammatory drug use
Am J Gastroenterol
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
N Engl J Med
Cited by (82)
Herbal bioactives in treatment of inflammation: An overview
2021, South African Journal of BotanyDiclofenac induced gastrointestinal and renal toxicity is alleviated by thymoquinone treatment
2018, Food and Chemical ToxicologyCitation Excerpt :Diclofenac also causes gastrointestinal (GI) damage via systemic inhibition of GI mucosal COX activity and thereby modulating arachidonic acid metabolism (Kanbayashi and Konishi, 2015). Diclofenac inhibits lipoxygenases, decreases the production of leukotrienes, suppresses prostaglandin synthesis and thromboxane-prostanoid receptor signaling (Scheiman and Hindley, 2010). Diclofenac is metabolized to 4-hydroxydiclofenac and other hydroxylated forms in the liver, after conjugation and sulfation, the metabolites are excreted mainly in the urine and bile (Kumar et al., 2002).
Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention
2017, Current Problems in CardiologyCitation Excerpt :These relative risks, which were derived from real-world settings, concur with those from randomized trials,18 and are not mitigated by the use of enteric-coated or buffered aspirin.19,20 Further, many of these bleeding episodes occur without prior symptoms. The adverse effects of aspirin on the GI tract are of sufficient frequency and potential severity that it is important to balance the risks of GI and CVD events when deciding on the advisability of prescribing aspirin to a particular patient.21,22 This is particularly problematic in those at increased CVD risk who have experienced a previous GI bleed.23
Facts and trends in dental antibiotic and analgesic prescriptions in Germany, 2012–2021
2024, Clinical Oral InvestigationsFrontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022
2023, Frontiers in Cardiovascular MedicineAcute Pain Management Pearls: A Focused Review for the Hospital Clinician
2023, Healthcare (Switzerland)